BioFinlandin jäsen

Orion's annual investment in pharmaceutical R&D for innovative medicines is over 10 % of the company's net sales. The company has R&D projects in both preclinical and clinical phases of the pipeline. Orion is actively looking for more research and development collaboration and partnering opportunities for the R&D value chain. Partnerships are elementary in the company's strategy, while in-house resources are distributed to research, preclinical as well as clinical according to the need. Core therapy areas for innovative medicines are pain and oncology.